BC Extra | Nov 26, 2019
Company News

Priority Review roundup: Roche-PTC, Intercept, Zogenix

FDA granted Priority Review to a trio of compounds Monday, accepting NDAs from partners Roche and PTC, as well as Intercept and Zogenix to treat neurological and hepatic diseases. Risdiplam from Roche (SIX:ROG; OTCQX:RHHBY) and...
BC Extra | Aug 26, 2019
Company News

Modis deal bolsters Zogenix’s late-stage, rare disease pipeline

With its acquisition of Modis, Zogenix will need to blaze a regulatory trail for Modis’ thymidine kinase 2 deficiency program while still pushing its own Dravet syndrome therapy through regulatory approval. Zogenix Inc. (NASDAQ:ZGNX) said...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BC Extra | Apr 8, 2019
Company News

Zogenix gets refusal-to-file letter for Dravet syndrome therapy

Zogenix was off $16.11 (31%) to $35.74 in early after-hours trading Monday after the company said FDA issued a refusal-to-file letter for an NDA for Fintepla (ZX008) to treat seizures associated with Dravet syndrome. Fintepla...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Aug 10, 2018
Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Aug. 7th. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill...
BC Extra | Aug 8, 2018
Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Tuesday. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill Lynch,...
Items per page:
1 - 10 of 237
BC Extra | Nov 26, 2019
Company News

Priority Review roundup: Roche-PTC, Intercept, Zogenix

FDA granted Priority Review to a trio of compounds Monday, accepting NDAs from partners Roche and PTC, as well as Intercept and Zogenix to treat neurological and hepatic diseases. Risdiplam from Roche (SIX:ROG; OTCQX:RHHBY) and...
BC Extra | Aug 26, 2019
Company News

Modis deal bolsters Zogenix’s late-stage, rare disease pipeline

With its acquisition of Modis, Zogenix will need to blaze a regulatory trail for Modis’ thymidine kinase 2 deficiency program while still pushing its own Dravet syndrome therapy through regulatory approval. Zogenix Inc. (NASDAQ:ZGNX) said...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BC Extra | Apr 8, 2019
Company News

Zogenix gets refusal-to-file letter for Dravet syndrome therapy

Zogenix was off $16.11 (31%) to $35.74 in early after-hours trading Monday after the company said FDA issued a refusal-to-file letter for an NDA for Fintepla (ZX008) to treat seizures associated with Dravet syndrome. Fintepla...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Aug 10, 2018
Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Aug. 7th. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill...
BC Extra | Aug 8, 2018
Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Tuesday. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill Lynch,...
Items per page:
1 - 10 of 237